Skip to main content
SpringerLink
Log in

Antineoplastics

Development of resistance in metastatic lung adenocarcinoma: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kibirova A, et al. The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. Case Reports in Oncology 12: 765-776, No. 3, Sep 2019. Available from: URL: http://doi.org/10.1159/000503417

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1794, 29 (2020). https://doi.org/10.1007/s40278-020-75825-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-75825-5

Search

Navigation